Observational studyCardiovascular diabetology2018
Prognostic impact of HbA1c variability on long-term outcomes in patients with heart failure and type 2 diabetes mellitus.
Observational study in Cardiovascular diabetology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A meta-analysis of the relationship between glycaemic variability and the mortality of patients with heart failure.ESC heart failure · 2024Pooled it
- Characteristics and long-term prognosis of patients with reduced, mid-range, and preserved ejection fraction: A systemic review and meta-analysis.Clinical cardiology · 2022Pooled it
- Prognostic value of HbA1c for in-hospital and short-term mortality in patients with acute coronary syndrome: a systematic review and meta-analysis.Cardiovascular diabetology · 2019Pooled it
- Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.Cardiovascular diabetology · 2019Trial
- The prognostic value of serum MgEndocrine · 2025Article
- Long-term outcomes prediction in diabetic heart failure with preserved ejection fraction by cardiac MRI.European radiology · 2024Article
- Glycated Hemoglobin Variability Is Associated With Adverse Outcomes in Patients With Heart Failure Irrespective of Diabetic Status.Journal of the American Heart Association · 2024Article
- Prognostic Implications of Type 2 Diabetes Mellitus in Heart Failure with Mildly Reduced Ejection Fraction.Journal of clinical medicine · 2024Article
- Long-term glycemic variability predicts compromised development of heart failure with improved ejection fraction: a cohort study.Frontiers in endocrinology · 2023Article
- Body Mass Index Enhances the Associations Between Plasma Glucose and Mortality in Patients with Acute Coronary Syndrome.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- Initial Invasive or Conservative Strategy in Heart Failure With Preserved Ejection Fraction and Coronary Artery Disease.Frontiers in cardiovascular medicine · 2022Article
- Risk stratification of cardiac arrhythmias and sudden cardiac death in type 2 diabetes mellitus patients receiving insulin therapy: A population-based cohort study.Clinical cardiology · 2021Observational
- Left ventricular geometry transition in hypertensive patients with heart failure with preserved ejection fraction.ESC heart failure · 2021Article
- Glycemic and lipid variability for predicting complications and mortality in diabetes mellitus using machine learning.BMC endocrine disorders · 2021Observational
- Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort.Cardiovascular diabetology · 2021Article
- Predictions of diabetes complications and mortality using hba1c variability: a 10-year observational cohort study.Acta diabetologica · 2021Observational
- Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications.Cardiovascular diabetology · 2021Review
- Diabetes in Patients With Heart Failure With Reduced Ejection Fraction During Hospitalization: A Retrospective Observational Study.Frontiers in endocrinology · 2021Observational
- Comparative predictive ability of visit-to-visit HbA1c variability measures for microvascular disease risk in type 2 diabetes.Cardiovascular diabetology · 2020Article
- Glycemic variability: adverse clinical outcomes and how to improve it?Cardiovascular diabetology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe prognostic impact of long-term glycemic variability on clinical outcomes in patients with heart failure (HF) and type 2 diabetes mellitus (T2DM) remains unclear. We determined and compared hemoglobin A1c (HbA1c) variability and clinical outcomes for patients with HF with preserved ejection fraction (HFpEF), HF with mid-range ejection fraction (HFmrEF) and HF with reduced ejection fraction (HFrEF) in a prospective longitudinal study.
methodsPatients with HF and T2DM, undergone 3 or more HbA1c determinations during the first 18 months, were then followed for 42 months. The primary outcome was death from any cause. Secondary outcome was composite endpoints with death and HF hospitalization. Cox proportional hazards models were used to compare outcomes for patients with HFpEF, HFmrEF and HFrEF.
resultsOf 902 patients enrolled, 32.2% had HFpEF, 14.5% HFmrEF, and 53.3% HFrEF. During 42 months of follow-up, 270 (29.9%) patients died and 545 (60.4%) patients experienced composite endpoints of death and HF readmission. The risk of all-cause death or composite endpoints was lower for HFpEF than HFrEF. Moreover, higher HbA1c variability was associated with higher all-cause mortality or composite endpoints and HbA1c variability was an independent predictor of all-cause mortality or composite endpoints, regardless of EF.
conclusionsThis prospective longitudinal study showed that the all-cause death and composite events was lower for HFpEF than HFrEF. HbA1c variability was independently and similarly predictive of death or combined endpoints in the three HF phenotypes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.